Read the Canadian Cancer Trial Group story on the interim results of the GCC.1 / S1823 study. Presented during the Genitourinary Cancer Session at the American Society of Clinical Oncology Annual Meeting 2026, the study focuses on patients with early-stage germ cell tumors and the blood biomarker microribonucleic acid (miRNA) 371a-3p (called miR371). These findings were presented by Dr. Lucia Nappi, study co-chair, clinician scientist and medical oncology at BC Cancer.